Stocks and InvestingStocks and Investing
Fri, March 22, 2024
Thu, March 21, 2024
Wed, March 20, 2024

Anupam Rama Maintained (BBIO) at Buy with Increased Target to $45 on, Mar 20th, 2024


Published on 2024-10-28 09:48:24 - WOPRAI, Anupam Rama
  Print publication without navigation


Anupam Rama of JP Morgan, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $35 to $45 on, Mar 20th, 2024.

Anupam has made no other calls on BBIO in the last 4 months.



There are 5 other peers that have a rating on BBIO. Out of the 5 peers that are also analyzing BBIO, 1 agrees with Anupam's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024


These are the ratings of the 4 analyists that currently disagree with Anupam


  • Josh Schimmer of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $70 on, Tuesday, March 19th, 2024
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $47 on, Monday, March 4th, 2024
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024